

HEALTHCARE WORKERS GUIDELINES

ON

RIFT VALLEY FEVER (RVF)

Developed by:
The National Institute for Communicable Diseases (NICD),
a division of the National Health Laboratory Service (NHLS)

Last updated: 17 May 2018 (adapted from 2010 version)



Table of contents

Disclaimer iii
Acknowledgements iii
1. Introduction and situation update 1
2. What is Rift Valley fever? 1
3. Previous outbreaks of RVF in South Africa 1
4. How is it transmitted to humans? 2
5. When should RVF be suspected as a cause of illness? Case definition and criteria for laboratory testing 2
6. What are the clinical features in humans? 3
7. How is it diagnosed in the laboratory? 3
8. Procedure following detection of a suspected case 4
Step 1: Notify the case 4
Step 2: Collect specimens for laboratory testing 4
9. How is it treated? Is there a vaccine? 4
10. Infection prevention and control in healthcare settings 5
11. How can RVF be prevented? 5
12. How are outbreaks prevented or mitigated? 5
13. Where can I get more information? 6
Rift Valley fever (RVF) suspected case investigation form, 2011 1

Disclaimer

This guideline is intended for use by healthcare professionals. While the greatest care has been taken in the development of this document, the National Department of Health and the National Institute for Communicable Diseases (NICD) of the National Health Laboratory Services (NHLS) do not accept responsibility for any errors or omissions. All healthcare professionals should exercise their own professional judgement in interpreting and applying the information presented in this guideline.

Acknowledgements

Many experts provided valuable input in the drafting of these guidelines, including colleagues from the South African National Department of Health, and the South African Department of Agriculture, Forestry and Fisheries.



1. Introduction and situation update

An isolated outbreak of Rift Valley fever has been detected on a single farm in the Jacobsdal area of Free State, South Africa, bordering Northern Cape. A total of 250 sheep deaths/abortions were documented and laboratory confirmed on 16 May 2018. No human cases have been detected thus far.

A widespread RVF epidemic occurred in South Africa in 2010-2011 with more than 14,000 animal cases recorded in 8 of 9 provinces. During this period the NICD confirmed a total of 278 human cases, of which 25 were fatal. Data from epidemiological investigations suggest that approximately 83% of these cases worked within occupations where direct contact with animals frequently occurs. Furthermore, 89% of cases reported a history of direct contact with RVF-infected animals prior to onset of symptoms. Human infections via mosquitoes and raw (unpasteurised/uncooked) milk were noted infrequently.

A decline in RVF transmission was noted during the colder winter months of the 2010-2011 epidemic. Nevertheless, following the confirmed animal cases in Jacobsdal in May 2018, all healthcare workers must be aware of RVF and be vigilant for patients who meet the case definition, and in such instances submit specimens to the NICD-NHLS for laboratory testing.

2. What is Rift Valley fever?

RVF is a zoonotic mosquito-borne viral disease of domestic and wild ruminants that can cause severe disease in a small proportion of infected humans. The virus is from the family *Phenuiviridae* (genus *Phlebovirus*) and causes outbreaks of abortions and deaths of young livestock (predominantly sheep, goats and cattle). The disease occurs throughout Africa and Middle East Asia when exceptionally heavy rains favour the breeding of the mosquito vectors. In RVF outbreaks occurring in east or southern Africa, humans become infected primarily from contact with infected tissues of livestock or wild (game) animals, and less frequently from mosquito bites. The mosquitoes which transmit the virus (*Aedes* and *Culex* mosquitoes) are present in South Africa; however, these species generally prefer to feed on livestock outdoors at night.

3. Previous outbreaks of RVF in South Africa

Cases of human RVF infections generally occur in the context of major outbreaks of disease in sheep, cattle and goats characterised by abortions and deaths of young animals. Outbreaks occur at irregular intervals of years following heavy rains that favour breeding of the mosquito vectors of the causative virus, and can recur over a succession of unduly wet seasons, but may not be seen for decades during drier spells.

Prior to the last major outbreak of RVF in 2010-2011 mentioned above, there was a 35 year interval before the previous large epidemic on the interior plateau of South Africa in 1974-76. In the 35 year interval, small sporadic outbreaks and human infections have been documented in KwaZulu-Natal, the Kruger National Park, Limpopo, Gauteng, North West, and Northern Cape provinces. During 2008 and 2009, relatively small focal RVF outbreaks were observed across Mpumalanga, Limpopo, Gauteng and North West provinces. These outbreaks affected both domestic livestock and wildlife. A number of human infections were identified among individuals in direct contact with the affected livestock (incl. farmers, farm workers, and animal health personnel).



4. How is it transmitted to humans?

- Direct or indirect contact with the blood or tissues of infected animals (the most common route of transmission in South Africa). This may include:
 - handling of animal tissue during slaughtering, butchering or skinning of animals,
 - assisting with animal births,
 - conducting veterinary procedures, and/or
 - disposal of carcasses or foetuses.
- Less common modes of transmission include:
 - inoculation, for example via a wound from an infected knife or needle-stick injuries or contact with broken skin,
 - inhalation of aerosols produced during the slaughter/necropsy of infected animals,
 - bites of infected mosquitoes (most commonly *Aedes*), and/or
 - consuming raw (unpasteurised or uncooked) milk from infected animals.
- No human-to-human transmission has ever been documented.

Occupational groups such as herders, farmers and farm workers, abattoir workers and veterinarians/animal health workers are at especially high risk of infection.

5. When should RVF be suspected as a cause of illness? Case definition & criteria for laboratory testing

A suspected case is defined as any person meeting **one or more** of the following criteria:

1. A person belonging to a high risk category and presenting with an influenza-like illness (which may include fever, myalgia, arthralgia or headache),
2. A person belonging to a high risk category and presenting with features of encephalitis, haemorrhage, hepatitis and/or ocular pathology (retinitis) \pm fever, **OR**
3. A person with unexplained encephalitis, hepatitis or haemorrhagic illness residing in an area where RVF can potentially occur.

High risk categories include:

1. Recent close contact with livestock/game animals in or from RVF-affected areas, including:
 - Slaughtering and butchering (traditional or commercial),
 - Disposal of carcasses/foetuses,
 - Assistance with birthing or other animal husbandry activities resulting in exposure to animal blood and body fluids, and/or
 - Veterinary procedures and necropsies.
2. Residing in an area where RVF is known to occur or has the potential to occur, with a history of recent mosquito bites.
3. Consumption of raw (unpasteurised/uncooked) milk sourced from RVF-affected areas.

Note: other causes for these symptoms must be excluded where appropriate, to facilitate timely treatment and appropriate infection prevention and control measures for other infections, including: malaria, Crimean-Congo haemorrhagic fever (CCHF) and tick-bite fever. Obtaining a thorough history including other signs and symptoms, recent travel, insect (e.g. tick) exposures, contact with livestock/game animals etc. will assist healthcare workers in narrowing the differential diagnosis.



6. What are the clinical features in humans?

Typically, illness is asymptomatic or mild in the vast majority of infected persons, with a small proportion experiencing severe disease. The true overall mortality rate following RVF infection is difficult to estimate given that case definitions and laboratory testing methods used in the various documented outbreaks differed significantly. Although the World Health Organization (WHO) Rift Valley fever fact sheet states an overall mortality rate of <1%, mortality rates noted in documented outbreaks range from <1% to 45%. The greatest number of laboratory-confirmed human cases in a single outbreak was recorded in the Saudi Arabian RVF outbreak during 2000, where the case fatality rate was 14.2%.

Mild illness

- The incubation period (interval from infection to onset of symptoms) for RVF varies from two to six days.
- Clinically, it presents as a fever with flu-like symptoms (including myalgia, arthralgia and headache).
- Some patients may also develop neck stiffness, sensitivity to light (photophobia), pain behind the eyes, loss of appetite and vomiting; in such patients the clinical presentation may be mistaken for meningitis.
- Symptoms of RVF usually last from four to seven days, after which time the immune response becomes detectable with the appearance of antibodies and the virus gradually disappears from the blood.

Severe illness

A small percentage of patients develop a much more severe form of the disease, which can manifest as one or more of the following complications:

- **Ocular disease (retinitis):** This may occur in up to 10% of infected patients. Onset of retinitis is usually one to three weeks after appearance of the first symptoms (which may be very mild or subclinical), and usually presents as painless blurred or decreased vision, or scotomata. It may resolve within 10 – 12 weeks with no sequelae. If lesions occur in the macula, up to 70% of patients will experience permanent loss of vision.
- **Meningoencephalitis:** The onset of meningoencephalitis usually occurs one to four weeks after the first symptoms (which may be very mild or subclinical) of RVF appear, and in some cases neurological complications can manifest >60 days after the initial symptoms of RVF. Clinical features may include: intense headache, loss of memory, hallucinations, confusion, disorientation, vertigo, convulsions, lethargy and coma. Although the mortality rate in patients who experience only this form of the disease is low, residual neurological deficit, which may be severe, is common.
- **Hepatitis:** This is characterised by markedly raised transaminase enzyme levels (ALT and AST), and may occur together with or precede other complications (e.g. haemorrhage or meningoencephalitis).
- **Renal failure:** Acute renal failure, characterised by elevated urea and creatinine levels, may be secondary to hypovolaemia, multiple-organ dysfunction, hepatorenal syndrome or possibly also direct virus-related injury.
- **Haemorrhagic fever:** Haemorrhagic manifestations appear two to four days after the initial onset of illness, and may present as haematemesis (vomiting blood), melaena (passing blood in the faeces), a petechial /purpuric rash or ecchymoses, bleeding from the nose or gums, menorrhagia, or bleeding from venepuncture sites. Thrombocytopenia is invariably present ± laboratory evidence of disseminated intravascular coagulation (DIC). Most cases also have evidence of hepatitis (markedly raised ALT and AST levels, or jaundice) which may precede the haemorrhagic state. The mortality rate of patients developing the haemorrhagic form of the disease is high (up to 65%).

7. How is it diagnosed in the laboratory?

Live virus or viral nucleic acid may be detected in blood during the early phase of illness or in post-mortem tissue by RT-PCR or isolation in cell cultures or mice. Haemagglutination inhibition assay (HAI) and enzyme-linked immunoassay (ELISA) tests



may confirm the presence of specific IgM and/or IgG antibodies to the virus. These tests are performed by the Centre for Emerging Zoonotic and Parasitic Diseases, NICD-NHLS.

8. Procedure following detection of a suspected case

Step 1: Notify the case

- RVF is a notifiable medical condition and should be notified using the Notifiable Medical Conditions (NMC) mobile or web App.

Step 2: Collect specimens for laboratory testing

- All suspected cases of RVF should have TWO clotted blood specimens (either red top tubes or SST-gel tubes which usually have a yellow top) of sufficient volume (± 5 ml each) taken for viral detection and antibody determination.
- In most cases a second, convalescent blood sample, collected 7-14 days after the acute blood sample is helpful in making a definitive diagnosis.
- The specimens should be packaged in accordance with the guidelines for the transport of dangerous biological goods (triple packaging using absorbent material) and transported directly to:

**Centre for Emerging Zoonotic and Parasitic Diseases
Arbovirus Reference Laboratory
National Institute for Communicable Diseases (NICD)
National Health Laboratory Service (NHLS)
No. 1 Modderfontein Rd
Sandringham, 2131
Gauteng, South Africa**

- ALL specimens should be labelled AND accompanied by a fully completed RVF suspected case investigation form (see page 7). These forms can also be emailed to the Centre for Emerging Zoonotic and Parasitic Diseases, NICD-NHLS, at petrusv@nicd.ac.za / veerlem@nicd.ac.za, or faxed to +27-(0)11-882-3741.
- Samples should be kept cold during transport (cold packs are sufficient).

The NICD-NHLS Hotline (082-883-9920) does **NOT** need to be contacted routinely for every case of suspected RVF. However, in the case of severely ill hospitalised patients where clinical advice is sought, or for whom laboratory testing needs to be prioritised and expedited, please call the NICD-NHLS Hotline (082-883-9920) which is a 24-hour service for all healthcare professionals countrywide. Please note that the NICD-NHLS Hotline is NOT a service for the general public, who should contact the Department of Health Hotline (086-136-4232) for any queries.

For RVF laboratory results contact the Centre for Emerging Zoonotic and Parasitic Diseases – Arbovirus Reference Laboratory, NICD-NHLS, at +27-(0)11-386 6391 / +27-(0)11-555 0503 during office hours (07h30-16h00).

9. How is it treated? Is there a vaccine?

- No specific approved treatment is available for RVF; management comprises general supportive therapy.
- Early dialysis for patients with renal failure may improve outcome.
- Beware of and promptly treat nosocomial infections, particularly in critically ill patients.
- Ribavirin is NOT recommended for treatment of RVF.
- Moderate to high dose corticosteroids are NOT recommended as adjunctive therapy for RVF.



Healthcare Workers Guidelines on Rift Valley fever. Updated 17 May 2018

- Standard infection prevention and control precautions should be followed (refer to section 10); patients do not require isolation or barrier nursing. Human-to-human transmission has not been demonstrated.
- Follow-up of patients for at least 1 month after symptoms resolve is advised to monitor for possible development of ocular complications (retinitis in particular) or neurological complications.
- There are no human RVF vaccines registered in South Africa for use by the general public.
- **Note:** Should a patient present with a haemorrhagic fever where both RVF and CCHF are differential diagnoses, manage as possible CCHF until laboratory test results are available, i.e.:
 - Implement appropriate infection prevention and control measures (including isolation and barrier nursing);
 - Start treatment with ribavirin as soon as possible; and
 - Notify laboratory or NICD-NHLS hotline that specimens need urgent processing to ensure a rapid result.

10. Infection prevention and control in healthcare settings

Although no human-to-human transmission of RVF has been demonstrated, there is still a theoretic risk of transmission from infected patients to healthcare workers through contact with infected blood or tissues. Healthcare workers caring for patients with suspected or confirmed RVF should implement “Standard Precautions”.

“Standard Precautions” define the work practices that are required to ensure a basic level of infection control, and are recommended in the care and treatment of all patients regardless of their perceived or confirmed infectious status. They cover the handling of blood (including dried blood), all other body fluids, secretions and excretions (excluding sweat), regardless of whether they contain visible blood, and contact with non-intact skin and mucous membranes. A two-page reminder with checklist can be downloaded at www.who.int/csr/resources/publications/EPR_AM2_E7.pdf

11. How can RVF be prevented?

Public health education and risk reduction plays a vital role in preventing human infections. Messages to the community, especially within affected areas should focus on:

- Avoiding high risk animal husbandry procedures and slaughtering practices through the use of gloves and other protective clothing, especially when handling sick animals.
- Avoiding the unsafe consumption of fresh blood, raw (unpasteurised or uncooked) milk or animal tissue. In outbreak regions, all animal products (blood, meat and milk) should be thoroughly cooked before eating. Slaughtering of sick animals for consumption should be discouraged during outbreaks.
- Personal and community protection against mosquito bites through the use of insect repellents (containing 30-50% DEET), insecticide-treated bed nets, and wearing of light-coloured clothing.

12. How are outbreaks prevented or mitigated?

Prevention of RVF outbreaks primarily relies on the prevention of infection in livestock through vaccination. Several veterinary (animal) vaccines are available in South Africa. Other ways in which to mitigate the spread of RVF involve control of the vector and protection against their bites. Larviciding measures at mosquito breeding sites are the most effective form of vector control if breeding sites can be clearly identified and are limited in size and extent. During periods of flooding, however, the number and extent of breeding sites is usually too high for larviciding measures to be feasible.



13. Where can I get more information?

- Regular updates and these guidelines are available through the NICD-NHLS website (www.nicd.ac.za).
- Questions from the general public can be directed to the Department of Health hotline:
 - 0861-DOH-CDC (0861-364-232)
- Additional information on RVF is available on the following website references:
 - World Health Organization. Rift Valley Fever. www.who.int/mediacentre/factsheets/fs207/en/.
 - Centers for Disease Control. www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/rvf.htm.



RIFT VALLEY FEVER SUSPECTED CASE INVESTIGATION FORM, 2018

Filled in by: _____ Contact number: (000) 0000000
Date: DD / MM / YYYY Information collected from: _____

PATIENT DETAILS

1. SURNAME, FIRST NAME: _____
2. AGE/DOB 00 years / DD / MM / YYYY 3. GENDER: MALE FEMALE
4. CONTACT NUMBER: (000) 0000000 (000) 0000000 (000) 0000000
5. OCCUPATION: _____ 6. FARM NAME: _____
7. TOWN: _____ DISTRICT: _____ PROVINCE: _____

CONSULTATION/ADMISSION DETAILS

8. NAME OF THE CLINICIAN: _____ 9. CELL/TEL NUMBER: (000) 0000000 (000) 0000000
10. FACILITY NAME: _____
11. DATE OF FIRST CONSULTATION: DD / MM / YYYY 12. SPECIMEN COLLECTION DATE: DD / MM / YYYY
13. ADMITTED TO HOSPITAL? Y N 14. REQUIRED ICU CARE? Y N
If yes, DURATION OF HOSPITAL ADMISSION? 00 (days) If yes, DURATION OF ICU CARE? 00 (days)

CLINICAL DETAILS ON FIRST PRESENTATION/ADMISSION

15. PAST MEDICAL HISTORY:
UNDERLYING ILLNESS? Y N ... If yes, WHAT? _____
IMMUNOSUPPRESSION? Y N ... If yes, GIVE DETAILS? _____
PAST RVFV INFECTION? Y N ... If yes, WHEN? _____ (month) 0000 (year)

16. DATE OF ONSET OF ILLNESS? DD / MM / YYYY

17. SYMPTOMS (tick all that apply):

| | | |
|---|--|---|
| <input type="checkbox"/> FEVER | <input type="checkbox"/> ABDOMINAL PAIN | 18. <input type="checkbox"/> HAEMORRHAGE (If yes, tick sites that apply): <input type="checkbox"/> EPISTAXIS <input type="checkbox"/> PETECHIAE BLEEDING <input type="checkbox"/> HAEMATEMESIS <input type="checkbox"/> FROM VENEPUNCTURE SITES <input type="checkbox"/> MELAENA <input type="checkbox"/> MENORRHAGIA <input type="checkbox"/> BLEEDING ELSEWHERE? Specify: _____ |
| <input type="checkbox"/> MYALGIA | <input type="checkbox"/> NECK STIFFNESS | |
| <input type="checkbox"/> ARTHRALGIA | <input type="checkbox"/> HEADACHE | |
| <input type="checkbox"/> FATIGUE | <input type="checkbox"/> OCULAR PAIN | |
| <input type="checkbox"/> MALAISE | <input type="checkbox"/> PHOTOPHOBIA | |
| <input type="checkbox"/> LOSS OF APPETITE | <input type="checkbox"/> BLURRED VISION | |
| <input type="checkbox"/> NAUSEA | <input type="checkbox"/> LOSS OF VISUAL ACUITY | |
| <input type="checkbox"/> VOMITING | <input type="checkbox"/> CONFUSION | |

19. EXAMINATION ON PRESENTATION (tick all that apply):

| | | | |
|--|--------------------------------------|------------------------------------|---|
| <input type="checkbox"/> FEVER ($\geq 38^{\circ}\text{C}$) | <input type="checkbox"/> DEHYDRATION | <input type="checkbox"/> MENINGISM | <input type="checkbox"/> HEPATOMEGALY |
| <input type="checkbox"/> SHOCK (\downarrow BP) | <input type="checkbox"/> JAUNDICE | <input type="checkbox"/> CONFUSION | <input type="checkbox"/> ABDOMINAL TENDERNESS |
| | <input type="checkbox"/> PALLOR | <input type="checkbox"/> RETINITIS | <input type="checkbox"/> RASH |

20. LIST OTHER CLINICAL FINDINGS?

21. CLINICAL PROGRESSION TO DATE? UNEVENTFUL RECOVERY or DEVELOPED COMPLICATIONS

... If developed complications, tick all that apply:

| | | |
|--|---|---------------------------------------|
| <input type="checkbox"/> ELEVATED TRANSAMINASE LEVELS (AST, ALT) | <input type="checkbox"/> THROMBOCYTOPENIA | <input type="checkbox"/> RETINITIS |
| <input type="checkbox"/> LIVER FAILURE | <input type="checkbox"/> HAEMORRHAGE | <input type="checkbox"/> ENCEPHALITIS |
| <input type="checkbox"/> RENAL FAILURE | | |

22. OUTCOME: ALIVE DIED ... If yes, DATE OF DEATH? DD / MM / YYYY

23. EXPOSURE (tick all that apply)

DATE OF EXPOSURE? DD / MM / YYYY
 CONTACT WITH ANIMALS/ TISSUES DRANK UNPASTEURISED MILK
 MOSQUITO BITES CONSUMED ANIMAL MEAT NOT SOURCED FROM RETAIL OUTLET
DESCRIPTION OF EXPOSURE: _____

POST COMPLETED FORM WITH SPECIMEN TO:

Arbovirus Reference Lab, National Institute for Communicable Diseases, National Health Laboratory Service,
1 Modderfontein Road, Sandringham 2192, South Africa

FAX OR EMAIL COMPLETED FORM TO:

0865964423/011 882 3741 or petrusv@nicd.ac.za / veerlem@nicd.ac.za / cezd@nicd.ac.za